Sanofi and Regeneron expand immunology partnership to the tune of $8bn
Having already brought one of the most successful drugs in the world to market, Sanofi and Regeneron are broadening their…
All articles by Robert Barrie
Robert Barrie
Robert Barrie is a news and features reporter for Pharmaceutical Technology. He holds a BSc in Neuroscience and his interests include infectious diseases, weight loss therapies, and health politics. Contact Rob
-
-
Atossa plans shareholder stake in potential PRV proceeds
Atossa Therapeutics has put in place a plan that would give its shareholders a share of any proceeds from the…
-
Novo inks $1.33bn long-lasting injectable pact with Sweden-based Nanexa
Novo has signed a license agreement with Nanexa to use the Swedish biotech’s longer-lasting drug delivery technology, as the company…
-
FDA commissioner nominee affirms MMR vaccine safety despite Trump’s claims
Dr Heidi Overton, Donald Trump’s nominee to lead the US Food and Drug Administration (FDA), has affirmed the safety and…
-
Eli Lilly outlays $3.35bn for secretive drug discovery pact with China’s InnoCare
Eli Lilly has partnered with China-based InnoCare Pharma in a five-drug strong research and license pact. As per the deal,…
-
Podcast: How Sandoz plans to harness its “golden decade”
At its Capital Markets Day on 8 September, Sandoz revealed a new set of targets – part of a roadmap…
-
European big pharma unites amid ‘ringing alarm bells’ of continent’s dominance
The boardrooms of all European big pharma companies have issued a stark warning regarding the current competitiveness of the continent’s…
-
Novo targets blockbuster-heavy 2030 but share slump signals unease
Shares in Novo have slumped despite the drugmaker outlining a five-year commercial strategy in a bid to return to winning…
-
Beijing unveils blueprint for biomedical dominance by 2030
The Chinese government has unveiled an ambitious five-year plan for its biomedical industry, as the country looks to cement its…
-
FDA approves first gene therapy for Sanfilippo syndrome type A
The US Food and Drug Administration (FDA) has approved Ultragenyx’s gene therapy for Sanfilippo syndrome type A, marking the first…